CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
27.69BHKD3.53B · vs all stocks (USD)
Revenue (TTM)
0.00HKDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-81.45%vs all stocks
Market Capitalization
27.69BHKD3.53B · vs all stocks (USD)
Enterprise Value
2.31BHKD295.06M · vs all stocks (USD)
Forward P/E
-31.66xvs Biotechnology peers
Price to Book (MRQ)
4.46xvs Biotechnology peers
Enterprise to EBITDA
-9.71xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-31.46%vs Biotechnology peers
Return on Equity (TTM)
-82.42%vs Biotechnology peers
Revenue (TTM)
0.00HKDvs all stocks (USD)
Revenue per Share (TTM)
0.00HKDUpdated Aug 19, 2026Gross Profit (TTM)
0.00HKDvs all stocks (USD)
EBITDA (TTM)
-238.45MHKD-30.40M · vs all stocks (USD)
Net Income (TTM)
-242.49MHKD-30.91M · vs all stocks (USD)
Operating Cash Flow (TTM)
-176.79MHKD-22.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-88.71MHKD-11.31M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
102.00KCNYFY2025 · Dec 31, 2025Revenue
0.00CNYFY2025 · Dec 31, 2025Cost of Goods Sold
0.00CNYFY2025 · Dec 31, 2025Gross Profit
0.00CNYFY2025 · Dec 31, 2025Operating Income
-205.91MCNY-30.54M · vs all stocks (USD)
Pre-tax Income
-208.55MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-208.55MCNYFY2025 · Dec 31, 2025EBIT
-205.77MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-204.42MCNYFY2025 · Dec 31, 2025Research & Development
50.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
37.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
378.38MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
378.38MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-208.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
185.00KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-128.33MCNYFY2025 · Dec 31, 2025Free Cash Flow
-131.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
467.54MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-208.55MCNYFY2025 · Dec 31, 2025Stock-based Compensation
82.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.53MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.66MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-30.00MCNYFY2025 · Dec 31, 2025Sale of Investments
131.57MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
97.91MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-143.42MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-15.02MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
362.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
391.09MSharesUpdated Aug 19, 2026Float Shares
151.53MSharesUpdated Aug 19, 2026% Held by Insiders
32.63%vs all stocks
% Held by Institutions
5.71%vs all stocks
Total Cash (MRQ)
607.51MHKD77.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.33HKDUpdated Aug 19, 2026Total Debt (MRQ)
108.94MHKD13.89M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2087xvs Biotechnology peers
Current Ratio (MRQ)
3.94xvs Biotechnology peers
Book Value per Share (MRQ)
1.33HKDUpdated Aug 19, 2026Total Assets
599.23MCNY88.87M · vs all stocks (USD)
Total Current Assets
556.28MCNYFY2025 · Dec 31, 2025Total Liabilities
150.64MCNYFY2025 · Dec 31, 2025Total Non-current Assets
42.95MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
9.59MCNYFY2025 · Dec 31, 2025Total Current Liabilities
141.06MCNYFY2025 · Dec 31, 2025Cash
467.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
467.54MCNYFY2025 · Dec 31, 2025Other Short-term Investments
54.47MCNYFY2025 · Dec 31, 2025Inventory
873.00KCNYFY2025 · Dec 31, 2025Accounts Payable
25.24MCNYFY2025 · Dec 31, 2025Short-term Debt
87.02MCNYFY2025 · Dec 31, 2025Long-term Debt
6.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
391.09MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.34BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
448.59MCNY66.53M · vs all stocks (USD)
52-Week Low
4.94HKDUpdated Aug 19, 202652-Week High
77.00HKDUpdated Aug 19, 202652-Week Change
-81.45%vs all stocks
50-Day MA
6.29HKDUpdated Aug 19, 2026200-Day MA
41.10HKDUpdated Aug 19, 2026Avg 10-Day Volume
21.58MSharesUpdated Aug 19, 2026Avg 30-Day Volume
25.39MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.6400HKDUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $3.53B, above the global median of $1.15BNotable
Market cap (USD): 3,530,492,528.083Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule